BCAX Stock Overview
A clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bicara Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.44 |
| 52 Week High | US$27.94 |
| 52 Week Low | US$21.05 |
| Beta | 0 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 8.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| BCAX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.7% | -2.9% | 0.9% |
| 1Y | n/a | 18.9% | 32.3% |
Return vs Industry: Insufficient data to determine how BCAX performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how BCAX performed against the US Market.
Price Volatility
| BCAX volatility | |
|---|---|
| BCAX Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: BCAX has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BCAX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 32 | Claire Mazumdar Clemon | www.bicara.com |
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Bicara Therapeutics Inc. Fundamentals Summary
| BCAX fundamental statistics | |
|---|---|
| Market cap | US$1.38b |
| Earnings (TTM) | -US$64.84m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-21.3x
P/E RatioIs BCAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BCAX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$64.84m |
| Earnings | -US$64.84m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.19 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BCAX perform over the long term?
See historical performance and comparison